Michele Thorpe, APRN
Psychiatric/Mental Health · Aberdeen, SDNPI 1285328039
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 32.0% of the total. 2025 is the largest year on record at $1,106, more than ten times the $46 reported in 2023.
Across 107 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$571
- Neurocrine Biosciences, Inc.$305
- Teva Pharmaceuticals USA, Inc.$249
- Axsome Therapeutics, Inc.$165
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$141
- Alkermes, Inc.$139
- plus $212 from 5 others
What the payments were for
- Food & beverage$1,67894%
- Education$1046%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $571 |
| Neurocrine Biosciences, Inc. | 19 | $305 |
| Teva Pharmaceuticals USA, Inc. | 9 | $249 |
| Axsome Therapeutics, Inc. | 4 | $165 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $141 |
| Alkermes, Inc. | 6 | $139 |
| Johnson & Johnson | 3 | $54 |
| Sage Therapeutics, LLC | 3 | $49 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$104
How this compares
$1,783 in reported general payments places this provider in the 80th percentile of 77 psychiatric/mental health providers in South Dakota.
See all psychiatric/mental health providers in South Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 22 | $178,656 |
| VraylarCariprazine Hcl | 57 | $65,858 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $28,073 |
| RexultiBrexpiprazole | 22 | $19,696 |
| Aripiprazole | 126 | $4,038 |
| Quetiapine Fumarate | 374 | $3,961 |
| Bupropion XlBupropion Hcl | 216 | $3,850 |
| Duloxetine Hcl | 236 | $2,950 |
| Trazodone Hcl | 238 | $2,578 |
| Olanzapine | 171 | $2,291 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $2,266 |
| Mirtazapine | 182 | $2,091 |
| Sertraline Hcl | 271 | $2,004 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 51 | $1,918 |
| Divalproex Sodium | 107 | $1,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $305 | $178,65622 claims |
| AbbVieVraylar | $571 | $65,85857 claims |
| Alkermes, Inc.Lybalvi | $139 | $28,07318 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $33 | $19,69622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 77 psychiatric/mental health providers in South Dakota.
Other psychiatric/mental health in Aberdeen
- Ginger ConklinAberdeen$1K
- Angela GaikowskiAberdeen$722
- Rhonda FliehsAberdeen$78
- Dione RoweWinner$152K
- Jennifer ErdmanRapid City$6K
- Nichole JohnsonSioux Falls$5K
- Andria PetersenSioux Falls$5K
- Christina CoffieldSpearfish$5K
- Carrie DyllaWatertown$4K
- Josie RiesWatertown$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.